Unlock instant, AI-driven research and patent intelligence for your innovation.

Levovitamin c-2-oxoacetyl-pakpak, its synthesis, activity and application

A technology of C-2-, oxyacetyl, which is applied in L-dimensional C-2-oxyacetyl-PAKPAK, can solve the problems of untreated ischemic stroke, unable to antagonize rat aortic strip relaxation, and unsatisfactory

Inactive Publication Date: 2021-02-12
CAPITAL UNIVERSITY OF MEDICAL SCIENCES
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

1,3-Dioxy-2-[(4-oxoacetic acid)phenyl]-4,4,5,5-tetramethylimidazoline-ARPAK, 1,3-dioxy-2-[(4 -oxyacetic acid)phenyl]-4,4,5,5-tetramethylimidazoline-GRPAK and 1,3-dioxy-2-[(4-oxoacetic acid)phenyl]-4,4,5 , 5-Tetramethylimidazoline-QRPAK can detect O free radicals, OH free radicals and NO free radicals on the ESR instrument (i.e. paramagnetic resonance instrument), but in the internationally recognized evaluation model (for acetylcholine-induced relaxation of rat aortic strips)
1,3-Dioxy-2-[(4-oxoacetic acid)phenyl]-4,4,5,5-tetramethylimidazoline-ARPAK, 1,3-dioxy-2-[(4 -oxyacetic acid)phenyl]-4,4,5,5-tetramethylimidazoline-GRPAK and 1,3-dioxy-2-[(4-oxoacetic acid)phenyl]-4,4,5 , the least desirable property of 5-tetramethylimidazoline-QRPAK is that it has no therapeutic effect on ischemic stroke

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Levovitamin c-2-oxoacetyl-pakpak, its synthesis, activity and application
  • Levovitamin c-2-oxoacetyl-pakpak, its synthesis, activity and application
  • Levovitamin c-2-oxoacetyl-pakpak, its synthesis, activity and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Embodiment 1 prepares levovitamin C-2-ethyl oxyacetate (1)

[0026]To a solution of 1.14g (28mmol) NaH (60%) and 10mL of anhydrous dimethylformamide (DMF) at 0°C, add 5.00g (28mmol) of levovitamin C in batches, bubbles appear, wait until there are no bubbles Finally, 5.42 g (28 mmol) of ethyl bromoacetate was added dropwise, and the reaction was stirred for 12 hours, and TLC showed that the reaction was complete. The solvent was removed from the reaction mixture under reduced pressure, and the resulting residue was purified by silica gel column chromatography to obtain 3.49 g (49%) of the title compound as a colorless syrup. ESI-MS(m / e):261[M-H] - ;Mp:177-179℃;[α] D 25 =-12.1 (c=0.1, MeOH), IR (KBr, cm -1 ):3333,1761,1676,1269,1247; 1 HNMR (300MHz, DMSO-d6): δ / ppm=4.94(m, 2H), 4.85(s, 1H), 4.15(q, J=0.6Hz, 2H), 3.83(m, 1H), 3.48(m, 2H), 1.20 (t, J=0.6Hz, 3H).

Embodiment 2

[0027] Embodiment 2 prepares L-vitamin C-2-oxoacetic acid (2)

[0028] Dissolve 3.49 g (13.3 mmol) of ethyl levovitamin-2-oxyacetate (1) in 10 mL of methanol, add 1 mL of water with stirring in an ice bath, and adjust the pH value to 12 with 2M NaOH aqueous solution. Stir in an ice bath for 12 h, and monitor the completion of the reaction by TLC. The reaction mixture was washed with 5% KHSO 4 The aqueous solution was adjusted to pH 7, and concentrated under reduced pressure to remove the solvent to obtain 2.52 g (89%) of the title compound as a colorless powder. ESI-MS(m / e):233[M-H] - .

Embodiment 3

[0029] Embodiment 3 prepares Boc-Pro-OSu

[0030] Dissolve 5.50g (25.6mmol) Boc-Pro in 30mL of anhydrous tetrahydrofuran (THF), add 6.32g (30.6mmol) dicyclohexylcarbodiimide (DCC) under ice-cooling, stir for 30min, add 3.24g (28.1 mmol) N-hydroxysuccinimide (HOSu), stirred for 12 h, and the reaction was monitored by TLC to complete. Dicyclohexylurea (DCU) was removed by filtration under reduced pressure, the filtrate was concentrated to dryness under reduced pressure, and the obtained residue was dissolved in ethyl acetate, and then washed with saturated NaHCO 3 The aqueous solution was washed three times, and the saturated NaCl aqueous solution was washed three times, and the organic phase was washed with anhydrous NaCl 2 SO 4 It was dried for 8 h, filtered under reduced pressure, and the filtrate was concentrated under reduced pressure to remove the solvent to obtain 6.64 g (83.2%) of the title compound as a colorless powder. ESI-MS(m / e):313[M+H] + .

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to View More

Abstract

The present invention discloses levorotatory dimension C-2-oxyacetyl-Pro-Ala-Lys-Pro-Ala-Lys of the following formula. It discloses its preparation method, discloses its thrombolytic activity, discloses its activity of treating cerebral thrombosis and discloses its activity of scavenging NO free radicals, so the present invention discloses its use in preparing thrombolytic activity and treating cerebral thrombosis drug And the application of preparing NO free radical scavenger.

Description

technical field [0001] The present invention relates to levovitamin-2-oxyacetyl-Pro-Ala-Lys-Pro-Ala-Lys, to its preparation method, to its thrombolytic effect, to its effect on treating cerebral thrombosis and to its removal of NO. The role of free radicals, so the present invention relates to its application in the preparation of thrombolytic drugs, the application in the preparation of drugs for the treatment of cerebral thrombosis and the application in the preparation of NO free radical scavenger. The invention belongs to the field of biomedicine. Background technique [0002] Ischemic stroke is a relatively common and serious cerebrovascular disease, characterized by high incidence, high mortality, high disability rate and high recurrence rate. At present, the clinical treatment of ischemic stroke faces the reality that there is no effective drug, especially for patients with stroke lasting more than 4 hours, either dying or being disabled. It is an important clinical...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K7/06A61K38/08A61P7/02A61P39/06
CPCA61K38/00C07K7/06
Inventor 赵明彭师奇王玉记吴建辉赵欣尉
Owner CAPITAL UNIVERSITY OF MEDICAL SCIENCES